Otis W. Brawley

b. 1959

Sits on 4 boards. Last updated September 28, 2026

Time on boards

Boards served
4
Current seats
4
Board service
14 years
Director since
2023

14 years of board service in total across 4 boards, counting each seat separately. Longest: Agilent Technologies Inc., 3 years.

3 years · Since 2023
Incyte Corp. Director
3 years · Since 2023
3 years · Since 2023
3 years · Since 2023

Shareholder support

Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Date Company Transaction Shares Price Value
Jun 8, 2026 Incyte Corp. Grant or award +1,642 — —
Mar 19, 2026 Agilent Technologies Inc. Grant or award +2,158 $111.75 $241,157
Mar 19, 2026 Agilent Technologies Inc. Grant or award +888 $111.75 $99,234
Jun 10, 2025 Incyte Corp. Grant or award +2,518 — —
Mar 31, 2025 Lyell Immunopharma Inc. Open-market purchase +35,640 $0.56 $19,958
Mar 14, 2025 Agilent Technologies Inc. Grant or award +1,819 $121.18 $220,426
Mar 14, 2025 Agilent Technologies Inc. Grant or award +812 $121.18 $98,398
Jun 12, 2024 Incyte Corp. Grant or award +2,830 — —
Mar 15, 2024 Agilent Technologies Inc. Grant or award +1,678 $147.48 $247,471
Mar 15, 2024 Agilent Technologies Inc. Grant or award +750 $147.48 $110,610
Jun 14, 2023 Incyte Corp. Grant or award +2,505 — —
Mar 16, 2023 Agilent Technologies Inc. Grant or award +1,658 $136.82 $226,848
Mar 16, 2023 Agilent Technologies Inc. Grant or award +741 $136.82 $101,384

Questions about Otis W. Brawley

What boards is Otis W. Brawley on?

Otis W. Brawley sits on the boards of Agilent Technologies Inc., Incyte Corp., Lyell Immunopharma Inc. and PDS Biotechnology Corporation.

How long has Otis W. Brawley served on boards?

Our records show at least 14 years of board service across 4 boards, the earliest from 2023.

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.